2022
Analysis of Tumor Burden as a Biomarker for Patient Survival with Neuroendocrine Tumor Liver Metastases Undergoing Intra-Arterial Therapies: A Single-Center Retrospective Analysis
Miszczuk M, Chapiro J, Do Minh D, van Breugel JMM, Smolka S, Rexha I, Tegel B, Lin M, Savic LJ, Hong K, Georgiades C, Nezami N. Analysis of Tumor Burden as a Biomarker for Patient Survival with Neuroendocrine Tumor Liver Metastases Undergoing Intra-Arterial Therapies: A Single-Center Retrospective Analysis. CardioVascular And Interventional Radiology 2022, 45: 1494-1502. PMID: 35941241, PMCID: PMC9587516, DOI: 10.1007/s00270-022-03209-9.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkersChemoembolization, TherapeuticHumansLiver NeoplasmsNeuroendocrine TumorsRetrospective StudiesTumor BurdenConceptsNeuroendocrine tumor liver metastasesMedian overall survivalIntra-arterial therapyLow tumor burdenTumor burdenOverall survivalLiver metastasesPrognostic factorsTumor diameterTB groupLonger median overall survivalRetrospective single-center analysisSingle-center retrospective analysisHigh TB groupLow TB groupRespective hazard ratiosHigh tumor burdenSingle-center analysisIndependent prognostic factorStrong prognostic factorDrug-eluting beadsLargest liver lesionPrediction of survivalHazard ratioPatient survivalResponse assessment methods for patients with hepatic metastasis from rare tumor primaries undergoing transarterial chemoembolization
Adam LC, Savic LJ, Chapiro J, Letzen B, Lin M, Georgiades C, Hong KK, Nezami N. Response assessment methods for patients with hepatic metastasis from rare tumor primaries undergoing transarterial chemoembolization. Clinical Imaging 2022, 89: 112-119. PMID: 35777239, PMCID: PMC9470015, DOI: 10.1016/j.clinimag.2022.06.013.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, HepatocellularChemoembolization, TherapeuticEthiodized OilHumansLiver NeoplasmsRetrospective StudiesTreatment OutcomeConceptsConventional transarterial chemoembolizationLipiodol depositionHepatic metastasesResponse assessment methodsPartial responseTransarterial chemoembolizationResponse assessmentTumor primaryStratification of responseRare primary tumorResponse Evaluation CriteriaRetrospective bicentric studyAssessment of responseQuantitative European AssociationLiver metastasesMajor complicationsBicentric studyPrimary tumorRare tumorEarly surrogateTreatment responseCT scanPatientsRECISTSolid tumorsOptimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI.
Borde T, Nezami N, Laage Gaupp F, Savic LJ, Taddei T, Jaffe A, Strazzabosco M, Lin M, Duran R, Georgiades C, Hong K, Chapiro J. Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI. Radiology 2022, 304: 228-237. PMID: 35412368, PMCID: PMC9270683, DOI: 10.1148/radiol.212426.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorCarcinoma, HepatocellularChemoembolization, TherapeuticHumansLiver NeoplasmsMagnetic Resonance ImagingMaleMiddle AgedNeoplasm StagingRetrospective StudiesTreatment OutcomeTumor BurdenConceptsMedian overall survivalAdvanced-stage hepatocellular carcinomaTransarterial chemoembolizationHepatocellular carcinomaBCLC BBCLC COverall survivalTumor burdenBarcelona Clinic Liver Cancer (BCLC) staging systemLiver Cancer staging systemCancer (AJCC) staging systemConventional transarterial chemoembolizationDrug-eluting beadsAllocation of patientsContrast-enhanced MRIBackground PatientsSurvival benefitRetrospective studyStaging systemC tumorsTumor volumePatientsHeterogeneous patientsMonthsChemoembolizationImpact of Chemoembolic Regimen on Immune Cell Recruitment and Immune Checkpoint Marker Expression following Transcatheter Arterial Chemoembolization in a VX2 Rabbit Liver Tumor Model
Berz AM, Santana JG, Iseke S, Gross M, Pekurovsky V, Laage Gaupp F, Savic LJ, Borde T, Gottwald LA, Boustani AM, Gebauer B, Lin M, Zhang X, Schlachter T, Madoff DC, Chapiro J. Impact of Chemoembolic Regimen on Immune Cell Recruitment and Immune Checkpoint Marker Expression following Transcatheter Arterial Chemoembolization in a VX2 Rabbit Liver Tumor Model. Journal Of Vascular And Interventional Radiology 2022, 33: 764-774.e4. PMID: 35346859, PMCID: PMC9344951, DOI: 10.1016/j.jvir.2022.03.026.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibiotics, AntineoplasticBicarbonatesCarcinoma, HepatocellularChemoembolization, TherapeuticDoxorubicinLiver NeoplasmsProgrammed Cell Death 1 ReceptorRabbitsConceptsTranscatheter arterial chemoembolizationCytotoxic T-lymphocyte-associated protein 4Rabbit liver tumor modelConventional TACEImmune checkpoint marker expressionLiver tumor modelVX2 rabbit liver tumor modelArterial chemoembolizationBicarbonate infusionImmune responseDifferentiation 3T-lymphocyte-associated protein 4Conventional transcatheter arterial chemoembolizationTumor modelCell death protein 1Marker expressionIntratumoral T cellsImmune checkpoint markersT cell infiltrationDeath protein 1Antigen-presenting cellsImmune cell recruitmentNew Zealand white rabbitsZealand white rabbitsAPC infiltration
2021
Quantitative Automated Segmentation of Lipiodol Deposits on Cone-Beam CT Imaging Acquired during Transarterial Chemoembolization for Liver Tumors: A Deep Learning Approach
Malpani R, Petty CW, Yang J, Bhatt N, Zeevi T, Chockalingam V, Raju R, Petukhova-Greenstein A, Santana JG, Schlachter TR, Madoff DC, Chapiro J, Duncan J, Lin M. Quantitative Automated Segmentation of Lipiodol Deposits on Cone-Beam CT Imaging Acquired during Transarterial Chemoembolization for Liver Tumors: A Deep Learning Approach. Journal Of Vascular And Interventional Radiology 2021, 33: 324-332.e2. PMID: 34923098, PMCID: PMC8972393, DOI: 10.1016/j.jvir.2021.12.017.Peer-Reviewed Original ResearchCarcinoma, HepatocellularChemoembolization, TherapeuticCone-Beam Computed TomographyDeep LearningEthiodized OilHumansLiver NeoplasmsComparison of metabolic and immunologic responses to transarterial chemoembolization with different chemoembolic regimens in a rabbit VX2 liver tumor model
Doemel LA, Santana JG, Savic LJ, Gaupp FML, Borde T, Petukhova-Greenstein A, Kucukkaya AS, Schobert IT, Hamm CA, Gebauer B, Walsh JJ, Rexha I, Hyder F, Lin M, Madoff DC, Schlachter T, Chapiro J, Coman D. Comparison of metabolic and immunologic responses to transarterial chemoembolization with different chemoembolic regimens in a rabbit VX2 liver tumor model. European Radiology 2021, 32: 2437-2447. PMID: 34718844, PMCID: PMC9359419, DOI: 10.1007/s00330-021-08337-3.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCarcinoma, HepatocellularChemoembolization, TherapeuticDoxorubicinEthiodized OilLiver NeoplasmsRabbitsTumor MicroenvironmentConceptsDrug-eluting embolicsImmune cell infiltrationAntigen-presenting cellsBicarbonate infusionConventional TACEDEE-TACETransarterial chemotherapyCell infiltrationImmune cellsPeritumoral infiltrationT lymphocytesIntratumoral immune cell infiltrationTumor modelRabbit VX2 liver tumor modelImmunological tumor microenvironmentVX2 liver tumor modelIntra-arterial therapyIntra-arterial treatmentRabbit VX2 tumor modelLiver tumor modelTumor-bearing rabbitsVX2 tumor modelMann-Whitney U testIntratumoral presenceTransarterial chemoembolizationLipiodol Deposition and Washout in Primary and Metastatic Liver Tumors After Chemoembolization
Nezami N, VAN Breugel JMM, Konstantinidis M, Chapiro J, Savic LJ, Miszczuk MA, Rexha I, Lin M, Hong K, Georgiades C. Lipiodol Deposition and Washout in Primary and Metastatic Liver Tumors After Chemoembolization. In Vivo 2021, 35: 3261-3270. PMID: 34697157, PMCID: PMC8627740, DOI: 10.21873/invivo.12621.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, HepatocellularChemoembolization, TherapeuticEthiodized OilHumansLiver NeoplasmsRetrospective StudiesConceptsConventional trans-arterial chemoembolizationTrans-arterial chemoembolizationNeuroendocrine tumorsColorectal carcinomaIntrahepatic cholangiocarcinomaLipiodol depositionWashout rateContrast-enhanced magnetic resonanceMetastatic liver tumorsColorectal carcinoma tumorsLiver metastasesHepatic metastasesTumor responseTarget lesionsRetrospective analysisLiver tumorsSmall tumorsChemoembolizationCarcinoma tumorsTumorsExponential washoutCarcinomaTomography imagingWashoutCholangiocarcinomaIdentifying enhancement-based staging markers on baseline MRI in patients with colorectal cancer liver metastases undergoing intra-arterial tumor therapy
Ghani MA, Fereydooni A, Chen E, Letzen B, Laage-Gaupp F, Nezami N, Deng Y, Gan G, Thakur V, Lin M, Papademetris X, Schernthaner RE, Huber S, Chapiro J, Hong K, Georgiades C. Identifying enhancement-based staging markers on baseline MRI in patients with colorectal cancer liver metastases undergoing intra-arterial tumor therapy. European Radiology 2021, 31: 8858-8867. PMID: 34061209, PMCID: PMC8848338, DOI: 10.1007/s00330-021-08058-7.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkersCarcinoma, HepatocellularChemoembolization, TherapeuticColorectal NeoplasmsHumansLiver NeoplasmsMagnetic Resonance ImagingRetrospective StudiesTumor BurdenConceptsColorectal cancer liver metastasesCancer liver metastasesTotal tumor volumeIntra-arterial therapyTotal liver volumeLiver metastasesTumor volumeTumor burdenTumor diameterPatient survivalBaseline MRILiver volumeMultivariable Cox proportional hazards modelsKaplan-Meier survival curvesWhole liverCox proportional hazards modelKaplan-Meier methodPrognostic staging systemSurvival of patientsColorectal cancer metastasisMethodsThis retrospective studyPre-treatment MRIProportional hazards modelAppropriate cutoff valueHR 1.7Lipiodol as an intra-procedural imaging biomarker for liver tumor response to transarterial chemoembolization: Post-hoc analysis of a prospective clinical trial
Letzen BS, Malpani R, Miszczuk M, de Ruiter QMB, Petty CW, Rexha I, Nezami N, Laage-Gaupp F, Lin M, Schlachter TR, Chapiro J. Lipiodol as an intra-procedural imaging biomarker for liver tumor response to transarterial chemoembolization: Post-hoc analysis of a prospective clinical trial. Clinical Imaging 2021, 78: 194-200. PMID: 34022765, PMCID: PMC8364875, DOI: 10.1016/j.clinimag.2021.05.007.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkersCarcinoma, HepatocellularChemoembolization, TherapeuticEthiodized OilHumansLiver NeoplasmsProspective StudiesRetrospective StudiesTreatment OutcomeConceptsConventional trans-arterial chemoembolizationMedian overall survivalProspective clinical trialsLipiodol depositionTumor responsePredictive biomarkersClinical trialsModified Response Evaluation CriteriaPost-TACE CTResponse Evaluation CriteriaMetastatic liver cancerKaplan-Meier analysisTrans-arterial chemoembolizationTumor response criteriaLiver tumor responsePrediction of survivalSelective drug targetingArterial embolizationLiver metastasesOverall survivalBland-Altman plotsTransarterial chemoembolizationPortal veinTumor respondersHepatocellular carcinomaRole of 3D quantitative tumor analysis for predicting overall survival after conventional chemoembolization of intrahepatic cholangiocarcinoma
Rexha I, Laage-Gaupp F, Chapiro J, Miszczuk MA, van Breugel JMM, Lin M, Konstantinidis M, Duran R, Gebauer B, Georgiades C, Hong K, Nezami N. Role of 3D quantitative tumor analysis for predicting overall survival after conventional chemoembolization of intrahepatic cholangiocarcinoma. Scientific Reports 2021, 11: 9337. PMID: 33927226, PMCID: PMC8085245, DOI: 10.1038/s41598-021-88426-x.Peer-Reviewed Original ResearchConceptsTotal tumor volumeConventional transarterial chemoembolizationTumor diameterIntrahepatic cholangiocarcinomaOverall survivalTumor areaICC patientsTumor volumeHigh tumor burden groupTumor analysisOS of patientsHazard ratioTransarterial chemoembolizationTumor burdenBurden groupConventional chemoembolizationHTB groupRetrospective analysisPatientsSurvival curvesMultivariate analysisChemoembolizationCholangiocarcinomaETVBaseline imagesAnatomy-guided multimodal registration by learning segmentation without ground truth: Application to intraprocedural CBCT/MR liver segmentation and registration
Zhou B, Augenfeld Z, Chapiro J, Zhou SK, Liu C, Duncan JS. Anatomy-guided multimodal registration by learning segmentation without ground truth: Application to intraprocedural CBCT/MR liver segmentation and registration. Medical Image Analysis 2021, 71: 102041. PMID: 33823397, PMCID: PMC8184611, DOI: 10.1016/j.media.2021.102041.Peer-Reviewed Original ResearchMeSH KeywordsAlgorithmsCarcinoma, HepatocellularChemoembolization, TherapeuticCone-Beam Computed TomographyHumansImage Processing, Computer-AssistedLiver NeoplasmsSpiral Cone-Beam Computed TomographyConceptsMultimodal registrationLiver segmentationLarge-scale manual annotationGround truthMultimodal image registrationMultimodal registration methodSegmentation networkDomain adaptationManual annotationSource modalityImage registrationRegistration frameworkSegmentationImage-guided interventionsRegistration methodMedical imagingDiagnostic medical imagingCorrect transformationLimited FOVStructure informationIntraprocedural CBCTImage qualitySegmenterExperimental resultsPatient dataThermal ablation alone vs thermal ablation combined with transarterial chemoembolization for patients with small (<3 cm) hepatocellular carcinoma
Chai NX, Chapiro J, Petukhova A, Gross M, Kucukkaya A, Raju R, Zeevi T, Elbanan M, Lin M, Perez-Lozada JC, Schlachter T, Strazzabosco M, Pollak JS, Madoff DC. Thermal ablation alone vs thermal ablation combined with transarterial chemoembolization for patients with small (<3 cm) hepatocellular carcinoma. Clinical Imaging 2021, 76: 123-129. PMID: 33592550, PMCID: PMC8217099, DOI: 10.1016/j.clinimag.2021.01.043.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, HepatocellularChemoembolization, TherapeuticCombined Modality TherapyFemaleHumansLiver NeoplasmsMaleMiddle AgedRetrospective StudiesTreatment OutcomeConceptsOverall survivalTransarterial chemoembolizationHepatocellular carcinomaThermal ablationTA groupEarly-stage hepatocellular carcinomaMedian overall survivalTherapy-naïve patientsKaplan-Meier analysisMaximum tumor diameterStage hepatocellular carcinomaLog-rank testDrug-eluting beadsSmall hepatocellular carcinomaTerms of TTPHIPAA-compliant IRBSignificant differencesLipiodol-TACELocoregional therapyBCLC stageComplication rateTreatment cohortsTumor diameterAFP levelsPatient groupCost-Effectiveness of Imaging Tumor Response Criteria in Hepatocellular Cancer After Transarterial Chemoembolization
Wu X, Chapiro J, Malhotra A. Cost-Effectiveness of Imaging Tumor Response Criteria in Hepatocellular Cancer After Transarterial Chemoembolization. Journal Of The American College Of Radiology 2021, 18: 927-934. PMID: 33484726, DOI: 10.1016/j.jacr.2020.12.019.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, HepatocellularChemoembolization, TherapeuticCost-Benefit AnalysisHumansLiver NeoplasmsRetrospective StudiesTreatment Outcome
2020
Comparison of Drug-Eluting Embolics versus Conventional Transarterial Chemoembolization for the Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
Wu X, Chapiro J, Malhotra A, Kothary N. Comparison of Drug-Eluting Embolics versus Conventional Transarterial Chemoembolization for the Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. Journal Of Vascular And Interventional Radiology 2020, 32: 2-12.e1. PMID: 33160827, DOI: 10.1016/j.jvir.2020.09.022.Peer-Reviewed Original ResearchAdolescentAdultAgedAged, 80 and overAntibiotics, AntineoplasticCarcinoma, HepatocellularChemoembolization, TherapeuticClinical Decision-MakingCost SavingsCost-Benefit AnalysisDecision Support TechniquesDecision TreesDisease ProgressionDoxorubicinDrug CarriersDrug CostsFemaleHumansLiver NeoplasmsMaleMiddle AgedModels, EconomicQuality of LifeQuality-Adjusted Life YearsTime FactorsTreatment OutcomeYoung AdultAutomated feature quantification of Lipiodol as imaging biomarker to predict therapeutic efficacy of conventional transarterial chemoembolization of liver cancer
Stark S, Wang C, Savic LJ, Letzen B, Schobert I, Miszczuk M, Murali N, Oestmann P, Gebauer B, Lin M, Duncan J, Schlachter T, Chapiro J. Automated feature quantification of Lipiodol as imaging biomarker to predict therapeutic efficacy of conventional transarterial chemoembolization of liver cancer. Scientific Reports 2020, 10: 18026. PMID: 33093524, PMCID: PMC7582153, DOI: 10.1038/s41598-020-75120-7.Peer-Reviewed Original ResearchConceptsConventional transarterial chemoembolizationLipiodol depositionTransarterial chemoembolizationLiver cancerPeripheral depositionLipiodol depositsTherapeutic efficacyNecrotic tumor areasBaseline MRITherapy optionsTumor responseTreatment responseTumor volumeLiver lesionsLipiodolH postTumor areaH-CTHounsfield unitsBiomarkersChemoembolizationHigh rateTumorsCancerImproved responseProspective study of Lipiodol distribution as an imaging marker for doxorubicin pharmacokinetics during conventional transarterial chemoembolization of liver malignancies
Savic LJ, Chapiro J, Funai E, Bousabarah K, Schobert IT, Isufi E, Geschwind JH, Stark S, He P, Rudek MA, Perez Lozada JC, Ayyagari R, Pollak J, Schlachter T. Prospective study of Lipiodol distribution as an imaging marker for doxorubicin pharmacokinetics during conventional transarterial chemoembolization of liver malignancies. European Radiology 2020, 31: 3002-3014. PMID: 33063185, DOI: 10.1007/s00330-020-07380-w.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, HepatocellularChemoembolization, TherapeuticDoxorubicinEthiodized OilHumansLiver NeoplasmsProspective StudiesTreatment OutcomeConceptsConventional transarterial chemoembolizationProspective clinical trialsTumor responseConventional TACEAdverse eventsTransarterial chemoembolizationLiver malignanciesClinical trialsMarker predictiveTumor volumeExact testChild-Pugh B classVolumetric tumor responseChild-Pugh BPeak concentrationNon-compartmental analysisFisher's exact testDose normalizationQuantitative European AssociationStandard non-compartmental analysisTime-concentration curveLiver criteriaLobar distributionDoxorubicin pharmacokineticsNeuroendocrine metastasesIdarubicin-Loaded ONCOZENE Drug-Eluting Bead Chemoembolization in a Rabbit Liver Tumor Model: Investigating Safety, Therapeutic Efficacy, and Effects on Tumor Microenvironment
Borde T, Gaupp F, Geschwind JF, Savic LJ, Miszczuk M, Rexha I, Adam L, Walsh JJ, Huber S, Duncan JS, Peters DC, Sinusas A, Schlachter T, Gebauer B, Hyder F, Coman D, van Breugel JMM, Chapiro J. Idarubicin-Loaded ONCOZENE Drug-Eluting Bead Chemoembolization in a Rabbit Liver Tumor Model: Investigating Safety, Therapeutic Efficacy, and Effects on Tumor Microenvironment. Journal Of Vascular And Interventional Radiology 2020, 31: 1706-1716.e1. PMID: 32684417, PMCID: PMC7541537, DOI: 10.1016/j.jvir.2020.04.010.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibiotics, AntineoplasticBiosensing TechniquesCell Line, TumorCell ProliferationChemoembolization, TherapeuticDiffusion Magnetic Resonance ImagingHydrogen-Ion ConcentrationIdarubicinLiver Neoplasms, ExperimentalMaleMicrospheresMultidetector Computed TomographyParticle SizeRabbitsTumor MicroenvironmentConceptsMultiparametric magnetic resonanceRabbit liver tumor modelDiffusion-weighted imagingLiver tumor modelDEE chemoembolizationDrug-eluting embolic transarterial chemoembolizationTumor microenvironmentTumor modelMale New Zealand white rabbitsTumor acidosisNew Zealand white rabbitsVX2 liver tumorsZealand white rabbitsLaboratory parametersTransarterial chemoembolizationBead chemoembolizationMultiparametric MRDCE MR imagingLiver enzymesPostprocedural increaseIntratumoral hypoxiaLiver tumorsEntire lesionTherapeutic mechanismChemoembolizationMolecular MRI of the Immuno-Metabolic Interplay in a Rabbit Liver Tumor Model: A Biomarker for Resistance Mechanisms in Tumor-targeted Therapy?
Savic LJ, Doemel LA, Schobert IT, Montgomery RR, Joshi N, Walsh JJ, Santana J, Pekurovsky V, Zhang X, Lin M, Adam L, Boustani A, Duncan J, Leng L, Bucala RJ, Goldberg SN, Hyder F, Coman D, Chapiro J. Molecular MRI of the Immuno-Metabolic Interplay in a Rabbit Liver Tumor Model: A Biomarker for Resistance Mechanisms in Tumor-targeted Therapy? Radiology 2020, 296: 575-583. PMID: 32633675, PMCID: PMC7434651, DOI: 10.1148/radiol.2020200373.Peer-Reviewed Original ResearchConceptsImmuno-oncologic therapiesConventional transarterial chemoembolizationTransarterial chemoembolizationIntratumoral immune cell infiltrationMR spectroscopyRabbit liver tumor modelPrussian blue iron stainingAntigen-presenting immune cellsIntra-arterial infusionImmune cell infiltrationNew Zealand white rabbitsLiver tumor modelImmune cell exclusionLiver cancer modelContrast material administrationT2-weighted MRIZealand white rabbitsT2-weighted imagingResistance mechanismsImmunosuppressive tumorHLA-DRCell infiltrationImmune cellsImmunohistochemistry stainingRing enhancementNeutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE
Schobert IT, Savic LJ, Chapiro J, Bousabarah K, Chen E, Laage-Gaupp F, Tefera J, Nezami N, Lin M, Pollak J, Schlachter T. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE. European Radiology 2020, 30: 5663-5673. PMID: 32424595, PMCID: PMC7483919, DOI: 10.1007/s00330-020-06931-5.Peer-Reviewed Original ResearchMeSH KeywordsAgedBlood PlateletsCarcinoma, HepatocellularChemoembolization, TherapeuticFemaleHumansInflammationKaplan-Meier EstimateLiver NeoplasmsLymphocytesMagnetic Resonance ImagingMaleMiddle AgedMultivariate AnalysisNeutrophilsPrognosisProgression-Free SurvivalProportional Hazards ModelsRetrospective StudiesTreatment OutcomeConceptsProgression-free survivalTreatment-naïve hepatocellular carcinomaShorter progression-free survivalPoor tumor responseDEB-TACELymphocyte ratioTumor responseHepatocellular carcinomaMagnetic resonance imagingTumor growthInflammatory biomarkersDrug-eluting bead transarterial chemoembolizationContrast-enhanced magnetic resonance imagingHigher baseline NLRHigher baseline plateletsRadiomic featuresVolumetric tumor responseLoco-regional therapyAlpha-fetoprotein levelsBead transarterial chemoembolizationKaplan-Meier analysisMethodsThis retrospective studyDifferential blood countQuantitative European AssociationNodular tumor growth
2019
Fluorodeoxyglucose PET for Monitoring Response to Embolotherapy (Transarterial Chemoembolization) in Primary and Metastatic Liver Tumors
Schobert I, Chapiro J, Pucar D, Saperstein L, Savic LJ. Fluorodeoxyglucose PET for Monitoring Response to Embolotherapy (Transarterial Chemoembolization) in Primary and Metastatic Liver Tumors. PET Clinics 2019, 14: 437-445. PMID: 31472741, DOI: 10.1016/j.cpet.2019.06.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, HepatocellularChemoembolization, TherapeuticFemaleFluorodeoxyglucose F18HumansInfusions, Intra-ArterialLiver NeoplasmsMagnetic Resonance ImagingMaleMiddle AgedMonitoring, PhysiologicMultimodal ImagingNeoplasm MetastasisPositron-Emission TomographyRadiopharmaceuticalsSensitivity and SpecificitySurvival AnalysisTomography, X-Ray ComputedTreatment OutcomeTumor MicroenvironmentConceptsTransarterial chemoembolizationLiver tumorsFluorine-18 fluorodeoxyglucose PETEfficacy of embolotherapyCross-sectional imaging techniquesMetastatic liver tumorsCancer cell glycolysisLocal recurrenceFluorodeoxyglucose PETTumor necrosisLiver cancerMorphologic changesCell glycolysisEmbolotherapyTumorsMonitoring responseIndividual molecular characteristicsMolecular characteristicsImaging techniquesChemoembolizationResponsePatientsRecurrencePETTherapy